Full Press Release Details
Immutep Announces Promising New Clinical Data from Triple Combination
Therapy in INSIGHT-003 Trial
SYDNEY, AUSTRALIA 24 May 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF. INSIGHT-003 is the first study evaluating eftilagimod alpha ( efti ), a soluble LAG-3 protein and MHC Class II agonist, in conjunction with standard-of-care anti-PD-1 therapy and doublet chemotherapy (carboplatin/pemetrexed).
The triple combination therapy remains well-tolerated and continues to show promising initial efficacy signals attaining a 67% overall response rate (ORR) and
91% disease control rate (DCR) in advanced or metastatic non-squamous 1st line non-small cell lung cancer patients (N=21). Notably, 81% (17/21) of patients had a PD-L1 Tumor Proportion Score (TPS) of <50%, who are less responsive to anti-PD-1 based therapy compared with PD-L1 high expressing patients.
The 67% ORR regardless of PD-L1 expression and
65% response rate in patients with PD-L1 TPS <50% for the triple combination compare favourably to reported results from a registrational trial of anti-PD-1 and doublet chemotherapy in the same patient population that yielded an ORR of 48% regardless of PD-L1 expression and a response rate of 40.8% in patients
with PD-L1 TPS <50%.
Immutep CSO, Dr. Fr d ric Triebel, said: Immutep has made
significant progress with our late-stage development planning to treat one of the largest cancer indications globally. We are uniquely positioned to address PD-L1 low (TPS
1-49%) and high (TPS >50%) expressing patients, representing roughly 65% of the non-small cell lung cancer patient population, with powerful chemo-free IO-IO approaches, and potentially the entire patient population when including the IO-IO-chemo combination being tested in INSIGHT-003. Powering both options is eftilagimod alpha, the only MHC Class II agonist in clinical development, safely generating a broad immune response to fight cancer.
Patients with high, low, and negative PD-L1 expression represent approximately 30%, 35%, and 35%, respectively, of the
1st line non-small cell lung cancer (1L NSCLC) patient population. Low and negative PD-L1 expressors (patients with a PD-L1 TPS
of 1-49% and <1%) are less responsive to anti-PD-(L)1 therapy compared to patients with high levels or PD-L1 TPS of 50%.
Unlike many immuno-oncology combinations (IO-IO) that focus on high PD-L1 expressing patients, compelling clinical results to date from the TACTI-002 Phase II trial suggest that efti may be uniquely positioned to effectively address low
and high PD-L1 expressors (~65% of 1L NSCLC patient population) through chemo-free IO-IO combinations, and potentially the entire NSCLC patient population, regardless of
PD-L1 expression, when adding the IO-IO-chemo triple combination.
Prof. Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF and lead investigator noted: These initial results are supportive
of efti s synergies with both anti-PD-1 therapy and chemotherapy in the clinical setting, and we are pleased with the data to date from this novel IO-IO-chemo combination. Efti s ability to safely engage such a robust immune response for cancer patients via MHC Class II agonism is truly unique, and we look
forward to providing more data from this triple combination therapy at a major medical conference this year.
INSIGHT-003 trial was recently expanded to enroll 50 patients across multiple sites based on the favourable safety and efficacy results, and additional data is expected to be presented at a major medical
conference in H2 CY2023.
INSIGHT-003 is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF. It is being
run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple combination therapy in front line
non-small cell lung cancer patients consisting of efti administered subcutaneously in conjunction with an existing approved
standard-of-care combination of anti-PD-1 therapy (pembrolizumab) and chemotherapy
(carboplatin and pemetrexed) delivered intravenously. The trial will assess the safety, tolerability, and initial efficacy of the combination.
Eftilagimod Alpha (Efti)
Efti is Immutep s proprietary soluble LAG-3 protein and MHC Class II
agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC
(major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological
molecules like IFN- and CXCL10 that further boost the immune system s ability to fight cancer.
Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).
is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Chris Basta, VP, Investor Relations and
Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
This announcement was authorised for release by the Board of Immutep Limited.
Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia